SLC5A2 and type 2 diabetes mellitus: SGLT2 inhibitors do decrease transaminases in patients with type 2 diabetes, but this is not thought to be haemodynamically mediated and, instead, probably reflects a reduction in visceral fat, accumulation of which is not thought to be a feature of HFrEF.18, 19, 20